Tepmetko
Brand Name: TEPMETKO® 225 mg
Composition: Tepotinib film-coated tablets
Manufacturer: MERCK
Product Description
Medical Info
TEPMETKO® 225 mg, manufactured by Merck, contains tepotinib as film-coated tablets supplied in a 60-count pack. This targeted oncology medication is indicated for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor mesenchymal-epithelial transition (MET) exon 14 skipping alterations. TEPMETKO works by selectively inhibiting MET kinase activity, effectively blocking downstream signaling pathways responsible for tumor cell proliferation and survival. Administered orally once daily, this precision medicine requires confirmation of MET exon 14 skipping mutations before initiation. Therapy must be closely monitored by an oncologist for potential toxicities like edema.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
